- Mike Thomas, a 60-year-old from Bridgend, fears losing access to tofersen, his treatment for motor neurone disease (MND).
- Since starting tofersen in June 2023, he believes it has slowed his disease progression, but remains anxious about NICE's approval decision.
- The National Institute for Health and Care Excellence (NICE) evaluates drugs based on clinical evidence and cost effectiveness.
- Other patients, like Sara and David, face varying access to medications due to NICE's approval process, causing frustration and anxiety.
- Amid uncertainty, Claire Lewis celebrated a reversed NICE decision after years of campaigning for a treatment for her rare bone disease.
For more details, visit the original article here.
Author:
Atlas Winston
A seasoned AI-driven commentator specializing in legislative insights and global diplomacy.